Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation
详细信息 查看全文
- 作者：Christopher E. Dandoy1 ; christopher.dandoy@cchmc.org" class="auth_mail" title="E-mail the corresponding author ; David Haslam2 ; Adam Lane1 ; Sonata Jodele1 ; Kathy Demmel1 ; Javier El-Bietar1 ; Laura Flesch1 ; Kasiani C. Myers1 ; Abigail Pate1 ; Seth Rotz1 ; Paulina Daniels1 ; Gregory Wallace1 ; Adam Nelson1 ; Heather Waters3 ; Beverly Connelly2 ; 3 ; Stella M. Davies1
- 关键词：Bloodstream infection ; Mucosal barrier injury laboratory-confirmed bloodstream infection ; Central line&ndash ; associated bloodstream infection ; CLABSI ; MBI-LCBI ; Transplant-associated thrombotic microangiopathy ; Hematopoietic stem cell transplantation
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：22
- 期：9
- 页码：1671-1677
- 全文大小：503 K
文摘
- •
Mucosal barrier injury laboratory-confirmed bloodstream infections lead to significant morbidity, mortality, and healthcare resource utilization in hematopoietic stem cell transplant patients.
- •
Mucosal barrier injury laboratory-confirmed bloodstream infections are associated with increased 1-year nonrelapse mortality after stem cell transplantation.
- •
Patients undergoing allogeneic stem cell transplantation develop mucosal barrier injury laboratory-confirmed bloodstream infections at a much higher rate than those undergoing autologous stem cell transplantation.